NASDAQ · TECX
Healthcare · Biotechnology
$27.91
Up+$0.20 (+0.72%)
Updated Sep 17, 2026, 2:10 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TECX closed at $27.91 after 20 trading sessions, down 24.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $28.50 | $29.23 | $27.68 | $27.91 | 188.42K |
| Sep 15, 2026 | $29.71 | $30.015 | $27.95 | $28.51 | 220.9K |
| Sep 14, 2026 | $29.39 | $30.73 | $29.38 | $29.71 | 145K |
| Sep 11, 2026 | $29.03 | $29.395 | $28.5575 | $29.05 | 154.98K |
| Sep 10, 2026 | $30.06 | $30.32 | $28.40 | $28.61 | 252.39K |
| Sep 9, 2026 | $30.18 | $30.995 | $29.81 | $30.48 | 133.37K |
| Sep 8, 2026 | $30.32 | $31.41 | $29.955 | $30.40 | 116.58K |
| Sep 4, 2026 | $29.85 | $31.1199 | $29.735 | $30.75 | 159.29K |
| Sep 3, 2026 | $30.68 | $32.52 | $29.45 | $29.92 | 140.39K |
| Sep 2, 2026 | $31.22 | $31.80 | $29.77 | $30.38 | 167.35K |
| Sep 1, 2026 | $30.00 | $31.97 | $28.96 | $31.22 | 240.75K |
| Aug 31, 2026 | $35.67 | $35.67 | $29.78 | $29.94 | 719.57K |
| Aug 28, 2026 | $36.11 | $36.955 | $34.95 | $35.62 | 157.79K |
| Aug 27, 2026 | $35.76 | $37.995 | $35.55 | $36.70 | 278.13K |
| Aug 26, 2026 | $37.41 | $38.8499 | $35.76 | $35.97 | 145.17K |
| Aug 25, 2026 | $36.52 | $38.12 | $36.52 | $37.71 | 144.46K |
| Aug 24, 2026 | $37.28 | $38.249 | $35.50 | $36.47 | 222.28K |
| Aug 21, 2026 | $36.42 | $38.23 | $36.375 | $37.63 | 188.56K |
| Aug 20, 2026 | $36.51 | $37.225 | $35.68 | $36.05 | 196.85K |
| Aug 19, 2026 | $37.10 | $37.50 | $36.07 | $37.04 | 199.97K |
The latest Smart Investors Daily articles mentioning TECX.
TECX research
Company profile and research snapshot.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Wells Fargo | Overweight | — |
| May 26, 2026 | Raymond James | Strong Buy | — |
| Apr 14, 2026 | Stifel | Buy | — |
| Jan 8, 2026 | Truist Securities | Buy | — |
| Sep 3, 2025 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
On August 6, Tectonic Therapeutic (NASDAQ:TECX) reported second quarter results built around two clinical wins rather than sales figures, since this is a clinical stage biotech company with no products on the market yet. The headline news is that both of its lead programs hit their scheduled marks this year, and the company says it […]
SeekingAlpha · Sep 2, 2026
Tectonic Therapeutic (TECX): TX45 CpcPH-HFpEF trial design, Merck CADENCE support, long cash runway & 2026â27 catalysts. See more details here.
SeekingAlpha · Aug 7, 2026
Abrdn Healthcare Investors biotech CEF: 6.4% NAV discount, 56% NAV gain, 12% gain-funded payout, key risks. Read my analysis here on HQH.
Benzinga · Aug 7, 2026
Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and lowers the price target from $101 to $93.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TECX.
